Programs
Our programs are focused on expanding the radiopharmaceutical
field through our own discovery programs and in collaboration
with our partners. CPDC’s expertise lies in both the pre-clinical
development of new diagnostic probes and advancing important
radiopharmaceuticals to the clinic and market.
Our programs are focused on expanding the radiopharmaceutical
field through our own discovery programs and in collaboration
with our partners. CPDC’s expertise lies in both the pre-clinical
development of new diagnostic probes and advancing important
radiopharmaceuticals to the clinic and market.
CD8
In individuals with healthy immune
responses, the body activates an influx
of CD8+ “killer” T-cells to the site of
disease/infection to kill the infected cells.
Cancer cells can sometimes evade the
immune system which results in no T-cell
migration to the tumour sites to destroy
the cancerous cells.
Immunotherapy makes cancer cells visible to the immune system, allowing T-cells to find and
destroy them. However, there is currently no functional imaging agent on the market for
monitoring CD8+ T-cell migration at the tumour.
CPDC has licensed the Centyrin ® platform from Janssen Biotech, Inc. for global exclusive use
to create novel molecular imaging probes against immunotherapy drug targets. The small,
simple protein is a fraction of the size of a monoclonal antibody (mAb) but has similar specificity
and potency as a mAb along with excellent tissue penetration and rapid clearance.
In collaboration with the Dana Farber Cancer Institute (Boston, MA), our preclinical program
focuses on the development of CD8 PET imaging agents using the Centyrin ® platform that will
allow physicians to identify patients with T-cell infiltration at the tumour in a non-invasive
manner and predict the clinical benefit from immunotherapies.
Immunotherapy makes cancer cells visible to the immune system, allowing T-cells to find and
destroy them. However, there is currently no functional imaging agent on the market for
monitoring CD8+ T-cell migration at the tumour.
CPDC has licensed the Centyrin® platform from Janssen Biotech, Inc. for global exclusive use
to create novel molecular imaging probes against immunotherapy drug targets. The small,
simple protein is a fraction of the size of a monoclonal antibody (mAb) but has similar specificity
and potency as a mAb along with excellent tissue penetration and rapid clearance.
In collaboration with the Dana Farber Cancer Institute (Boston, MA), our preclinical program
focuses on the development of CD8 PET imaging agents using the Centyrin® platform that will
allow physicians to identify patients with T-cell infiltration at the tumour in a non-invasive
manner and predict the clinical benefit from immunotherapies.
